Ryohei Yanoshita
Hoshi University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ryohei Yanoshita.
The Journal of Infectious Diseases | 2004
Miho Watanabe; Koji Matsuoka; Eiji Kita; Katsura Igai; Nobutaka Higashi; Atsushi Miyagawa; Toshiyuki Watanabe; Ryohei Yanoshita; Yuji Samejima; Daiyo Terunuma; Yasuhiro Natori; Kiyotaka Nishikawa
Shiga toxin (Stx) is a major virulence factor in infection with Stx-producing Escherichia coli (STEC). We developed a series of linear polymers of acrylamide, each with a different density of trisaccharide of globotriaosylceramide (Gb3), which is a receptor for Stx, and identified Gb3 polymers with highly clustered trisaccharides as Stx adsorbents functioning in the gut. The Gb3 polymers specifically bound to both Stx1 and Stx2 with high affinity and markedly inhibited the cytotoxic activities of these toxins. Oral administration of the Gb3 polymers protected mice after administration of a fatal dose of E. coli O157:H7, even when the polymers were administered after the infection had been established. In these mice, the serum level of Stx was markedly reduced and fatal brain damage was substantially suppressed, which suggests that the Gb3 polymers entrap Stx in the gut and prevent its entrance into the circulation. These results indicate that the Gb3 polymers can be used as oral therapeutic agents that function in the gut against STEC infections.
Infection and Immunity | 2006
Miho Watanabe; Katsura Igai; Koji Matsuoka; Atsushi Miyagawa; Toshiyuki Watanabe; Ryohei Yanoshita; Yuji Samejima; Daiyo Terunuma; Yasuhiro Natori; Kiyotaka Nishikawa
ABSTRACT We previously developed linear polymers bearing clustered trisaccharides of globotriaosylceramide (Gb3) as orally applicable Shiga toxin (Stx) neutralizers. Here, using a Gb3 polymer with a short spacer tethering the trisaccharide to the core, we found that shortening the spacer length markedly reduced the binding affinity for Stx2 but not Stx1. Moreover, mutational analysis revealed that the essential binding sites of the terminal trisaccharides were completely different between Stx1 and Stx2. These results provide the molecular basis for the interaction between Stx B subunits and Gb3 polymers.
Toxicon | 1999
Ryohei Yanoshita; A. Kasuga; Seiji Inoue; Kiyoshi Ikeda; Yuji Samejima
A novel peptide has been isolated from the venom of Agkistrodon halys blomhoffii using a bioassay that monitors the stimulant effect on rat stomach fundus. The 11-amino acid peptide, named blomhotin, was purified to homogeneity by gel-filtration column chromatography and reverse-phase HPLC. The amino acid sequence of blomhotin was determined to be pGlu-Gly-Arg-Pro-Pro-Gly-Pro-Pro-Ile-Pro-Arg, which is similar to that of bradykinin-potentiating peptides which themselves cause no contraction of smooth muscle. The contraction induced by blomhotin showed homologous desensitization, implicating the involvement of a blomhotin-specific site in the response.
Scientific Reports | 2018
Miho Watanabe-Takahashi; Shinji Yamasaki; Masayuki Murata; Fumi Kano; Jun Motoyama; Jyoji Yamate; Jumpei Omi; Waka Sato; Hirofumi Ukai; Kentaro Shimasaki; Masaya Ikegawa; Miwa Tamura-Nakano; Ryohei Yanoshita; Yuri Nishino; Atsuo Miyazawa; Yasuhiro Natori; Noriko Toyama-Sorimachi; Kiyotaka Nishikawa
Shiga toxin (Stx), a major virulence factor of enterohemorrhagic Escherichia coli (EHEC), is classified into two subgroups, Stx1 and Stx2. Clinical data clearly indicate that Stx2 is associated with more severe toxicity than Stx1, but the molecular mechanism underlying this difference is not fully understood. Here, we found that after being incorporated into target cells, Stx2, can be transported by recycling endosomes, as well as via the regular retrograde transport pathway. However, transport via recycling endosome did not occur with Stx1. We also found that Stx2 is actively released from cells in a receptor-recognizing B-subunit dependent manner. Part of the released Stx2 is associated with microvesicles, including exosome markers (referred to as exo-Stx2), whose origin is in the multivesicular bodies that formed from late/recycling endosomes. Finally, intravenous administration of exo-Stx2 to mice causes more lethality and tissue damage, especially severe renal dysfunction and tubular epithelial cell damage, compared to a free form of Stx2. Thus, the formation of exo-Stx2 might contribute to the severity of Stx2 in vivo, suggesting new therapeutic strategies against EHEC infections.
Biological & Pharmaceutical Bulletin | 2008
Yuko Ogawa; Masami Kanai-Azuma; Yoshihiro Akimoto; Hayato Kawakami; Ryohei Yanoshita
Biological & Pharmaceutical Bulletin | 2011
Yuko Ogawa; Yuri Miura; Akira Harazono; Masami Kanai-Azuma; Yoshihiro Akimoto; Hayato Kawakami; Teruhide Yamaguchi; Tosifusa Toda; Tamao Endo; Masayoshi Tsubuki; Ryohei Yanoshita
Toxicon | 2008
Yuko Ogawa; Masami Kanai-Azuma; Yoshihiro Akimoto; Hayato Kawakami; Ryohei Yanoshita
Comparative Biochemistry and Physiology B | 2006
Yuko Ogawa; Yoshie Mamura; Nobuhiro Murayama; Ryohei Yanoshita
FEBS Journal | 2000
Nobuhiro Murayama; Gilles Michel; Ryohei Yanoshita; Yuji Samejima; Ken-ichi Saguchi; Hiroaki Ohi; Yoshiaki Fujita; Shigesada Higuchi
Toxicon | 2006
Ryohei Yanoshita; Yuko Ogawa; Nobuhiro Murayama; Tamotsu Omori-Satoh; Ken-ichi Saguchi; Shigesada Higuchi; Orawan Khow; Lawan Chanhome; Yuji Samejima; Visith Sitprija